I-Mab, a Phase III Shanghai immunoncology-autoimmune biopharma, announced the terms for its $100 million IPO on the NASDAQ exchange at a market value of $750 million. BeiGene, a Beijing company ...
-
-
Recent Updates
- Vibrant Start for the 2026 Jiefangbei International Consumption Festival in Chongqing
- China, US agree to $30 billion tariff cut, AI dialogue during Xi visit, China foreign ministry says
- China, US agree to $30 billion tariff cut, AI dialogue during Xi visit
- CELEBRATING THE WORLD OF ALILA, ALILA SHANGHAI MARKS SECOND ANNIVERSARY WITH EXCLUSIVE “GATHERING” EVENT
- [China] Breaking News! Shanghai RAAS to Acquire 100% of Boehringer Ingelheim’s Chinese Biopharmaceutical Business
- Chinese Banks Cease Retail Leveraged Precious-Metals Trading Following Shanghai Gold Exchange’s Directive
- CELEBRATING THE WORLD OF ALILA, ALILA SHANGHAI MARKS SECOND ANNIVERSARY WITH EXCLUSIVE “GATHERING” EVENT
- China’s ‘Lipstick King’ confronts slower growth, AI disruption in livestream shopping
- Taking China’s fastest bullet train: Beijing to Shanghai in first class
- Taking China’s fastest bullet train: Beijing to Shanghai in first class
Blogroll